Immunotherapy developments and new agents for locally advanced NSCLC and SCLC
Immunotherapy developments and new agents for locally advanced NSCLC and SCLC
Updates on triple-negative breast cancer and immunotherapy
Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA
Predictive and prognostic biomarkers for immunotherapy in lung cancer
Gynaecological cancer: New targets and immunotherapy developments
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
Botensilimab plus balstilimab for metastatic heavily pretreated microsatellite stable colorectal cancer
Rationale for routine use of IORT for early breast cancer and data for specific indications
Lisocabtagene maraleucel is efficacious at treating R/R chronic lymphocytic leukaemia/small lymphocytic lymphoma
ASCO 2023: Lung cancer research highlights
Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment
Venetoclax and ibrutinib therapy shows favourable results in the treatment of R/R chronic lymphocytic leukaemia